Dossier assessment
Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V
Report documents
-
Extract of dossier assessment
Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V
-
Dossier assessment
Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V
Dossier assessment
Adults with moderate to severe atopic dermatitis who are candidates for systemic treatment
Indication of a non-quantifiable added benefit
Press releases
Dupilumab for neurodermatitis: indication of an added benefit in adults
Additional information
Federal Joint Committee (G-BA)
2018-05-17 A G-BA decision was published.
Project details
- Project no.
- A17-63
- Commission
- Commission awarded on 01.12.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in children >= 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in adults and adolescents 12 years and above) – Benefit assessment according to §35a
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed